TrialBreast cancer research and treatment2021

A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.

Sara M Balch et al.PubMed ↗Publisher ↗

No numbers read from the abstract.